Structured Session

Lisbon Addictions 2022

How to Develop Global Surveys, Guidelines, Checklists and Consensus Statements in Prevention and Treatment of Addiction: New Innovations in the Pandemic Era

Thursday, November 24, 16:50

Lisbon Congress Centre, Insights Zone 4 (14)

Alexander Baldacchino

Drug Market and Use Changes During the COVID-19 Pandemic: A Global Survey

Hamed Ekhtiari

A Methodological Checklist for fMRI Cue Reactivity Studies in Addictions: Development and Expert Consensus

Antonio Verdejo-Garcia

Cognitive Training and Rehabilitation Approaches for Addiction: A Delphi Consensus

Tara Rezapour

Translating Neuroscience into Addiction Prevention: A Delphi Consensus Study

Arash Khojasteh Zonoozi

Global Experts-centered Consensus Development; A Series of Methodologies for Extending Harmonization and Global Representativeness in Addiction Science

Marc Potenza, Hamed Ekhtiari

How to Expand Expert-centered Methodologies within Various Areas of Addiction Science in a Global Level? A Discussion on First-hand Experiences in the Field and the Opportunities and Challenges on the Road Ahead

LISBON ADDICTIONS 2022

ISAM International Society of Addiction Medicine

ISAM

Global Expert Network

GEN

How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era

LISBON ADDICTIONS 2022

Welcome to ISAM-GEN Symposium!

Hamed Ekhtiari, MD, PhD
ISAM-GEN Secretary
University of Minnesota, USA

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

ISAM Global Expert Network GEN

UNIVERSITY OF MINNESOTA
Driven to Discover®

November 24, 2022

A. Global Distribution of Individual Addiction Experts



B. Global Distribution of Addiction Societies/Associations



World Addiction Medicine Reports: Study Protocol for the International Society of Addiction Medicine (ISAM) Global Expert Network (ISAM-GEN) Surveys

AUTHORS
Hamed Ekhtiari, Arash Khojasteh Zonoozi, Parnian Rafei, Fateme Sadat Abolghasemi, Daniel Pemstein, Tarek A Gawad, Sophia Achab, Hamad Al Ghaferi, Mustafa Al'Absi, Michaël Bisch, Aldo Al
Roshan Bhad, Kathleen Brady, Gregory Bunt, Anja Busse, Jenna Butner, Ahmad Danesh, Joseph El-Khoury, Fatima El Omari, Darius Jokūbonis, Cornelis De Jong, Geert Dom, Mohsen Ebrahimi, A
Singer, Dario Gigena Parker, Susumu Higuchi, Preethy Kathiresan, Emira Khelifa, Christos Kouimtsidis, Evgeny M. Krupitsky, Icro Maremmani, Garrett McGovern, Hossein Mohades Ardabili, Vla
Solomon Tshimong Rataemane, Arshiya Sangchooli, Goodman Sibeko, Anna Maria Vella, Salvador Benjamin D Vista, Mehran Zare-Bidoky, Min Zhao, Afzal Javed, Marc N. Potenza, Alex Baldacch

AUTHOR ASSERTIONS
Conflict of Interest: No
Public Data: Not applicable
Preregistration: Not applicable

SCAN ME

A. Global Distribution of Individual Addiction Experts



B. Global Distribution of Addiction Societies/Associations



Neuroscience-Informed Classification of Prevention Interventions in Substance Use Disorders: An RDoC-based Approach

Tara Rezapour, Parnian Rafei, Alex Baldacchino, Patricia J. Conrod, Geert Dom, Diana H. Fishbein, Ate
Vincent Hendriks, Nicola Newton, Nathaniel R. Riggs, Lindsay M. Squeglia, Maree Teesson, Jasmin Vas
Antonio Verdejo-Garcia, Hamed Ekhtiari

doi: https://doi.org/10.1101/2022.09.28.22280342

SCAN ME









Cognitive training and remediation interventions for substance use disorders: A Delphi consensus study

Antonio Verdejo-Garcia, Tara Rezapour, Emily Giddens, Arash Khojasteh Zonoozi, Parnian Rafe
Jamie Berry, Alfonso Caracuel, Marc L. Copersino, Matt Field, Eric L. Garland,
Valentina Lorenzetti, Leandro Malloy-Diniz, Victoria Manning, Ely M. Marceau,
David L. Pennington, Justin Strickland, Reinout Wiers, Rahia Fairhead, Alexandra Anderson,
Morris Bell, Wouter J. Boendermaker, Samantha Brooks, Raimondo Bruno, Salvatore Campa
Janna Cousijn, Miles Cox, Andrew C. Dean, Karen D Ersche, Ingmar Franken, Brett Froeliger,
Pedro Gamito, Thomas E. Gladwin, Priscila D. Goncalves, Katrijn Houben, Joanna Jacobus, Andrew
Anne M. Kaag, Johannes Lindenmeyer, Elly McGrath, Talia Nardo, Jorge Oliveira,
Charlotte R. Pennington, Kelsey Perrykkad, Hugh Piercy, Claudia I Rupp, Mieke H. J. Schulte,
Lindsay M. Squeglia, Petra Staiger, Dan J Stein, Jeff Stein, Maria Stein, William W. Stoops,
Mary Sweeney, Hoa Vo, Katie Witkiewitz, Steven P Woods, Richard Yi, Min Zhao, Hamed Ekhtiari

doi: https://doi.org/10.1101/2022.07.28.22278144

SCAN ME

ISAM GEN Global Expert Network

Jenna Butner

Ahmad Danesh

Aldo Alberto Conti

Parnian Rafei

Mehran Zare-Bidoky

Mohsen Ebrahimy

Ali Fathi Jouzdani

Hossein Mohaddes Ardabili

Preethy Kathiresan

Arshiya Sangchooli

Jiang Long



Your Name

How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era

LISBON ADDICTIONS 2022

Development of a Global Expert Survey Infrastructure and Longitudinal Surveys in Addiction Medicine

Marc Potenza, MD, PhD
ISAM Board Member
ISAM-GEN Secretary
Yale School of Medicine, USA

ISAM Global Expert Network

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

November 24, 2022

How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era

LISBON ADDICTIONS 2022

ISAM-GEN Pilot Survey: Global Survey on Treatment Service Provision for Opioid Use Disorder

ISAM Global Expert Network GEN

Arash Khojasteh Zonoozi
Fatemeh Sadat Abolghasemi
ISAM-GEN Assistant Officers
Mashhad University of Medical Sciences, Iran

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

October 4, 2022

How to develop global surveys, guidelines, checklists and consensus statements in prevention and treatment of addiction: new innovations in the pandemic era

LISBON ADDICTIONS 2022

ISAM GEN as a VICONS

Hamed Ekhtiari
ISAM-GEN Secretary
University of Minnesota, USA

ISAM Global Expert Network GEN

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

October 4, 2022

LISBON ADDICTIONS 2022

UNIVERSITY OF MINNESOTA Driven to Discover℠
MEDICAL DISCOVERY TEAM ON ADDICTION

UNIVERSITY OF MINNESOTA Driven to Discover®

LIBR Laureate Institute for Brain Research

ISAM Global Expert Network as a VICONS

SCAN ME

Lisbon Addiction Meeting
24 November 2022

Hamed Ekhtiari, MD, PhD

Department of Psychiatry and Behavioral Sciences, University of Minnesota

Center for Neural Circuits in Addiction, Department of Neuroscience, University of Minnesota

LISBON ADDICTIONS 2022

What is



Virtual Collaborative Networks in Science?

Promoting Diversity, Equity and Global Representativeness

Scientific Rigor, Open Research Consortiums, and Joint Decision Making

VICONS

SCAN ME

Let’s Start with an Example: ACRI


0 10 20 30 40 50

60 70 80 90 100

Addiction Cue Reactivity

JAMA Psychiatry | Original Investigation

Association of Drug Cues and Craving With Drug Use and Relapse
A Systematic Review and Meta-analysis

Nilofar Vafaie, MS; Hedy Kober, PhD

CONCLUSIONS AND RELEVANCE Findings from this systematic review and meta-analysis suggest that drug cue and craving indicators play significant roles in drug use and relapse outcomes and are an important mechanism underlying SUDs. Clinically, these results support incorporating craving assessment across stages of treatment, as early as primary care.

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2022.1240
Published online June 1, 2022.

Developing a VICONS with Addiction Cue Reactivity



(Afsarmanesh et al., 2005)

Developing a VICONS with Addiction Cue Reactivity



1. Networking: Involves communication and information exchange for mutual benefit
    - Sharing experiences through webinars
    - Sharing cue databases and tasks

(Afsarmanesh et al., 2005)



Methamphetamine and Opioid Cue Database (MOCD)

Drug and Alcohol Dependence 209 (2020) 107941

Neutral < Craving

NeuroImage
Volume 238, September 2021, 118180

It is never as good the second time around: Brain areas involved in salience processing habituate during repeated drug cue exposure in treatment engaged abstinent methamphetamine and opioid users

Hamed Ekhtiari, Rayus Kuplicki, Robin L. Aupperle, Martin P. Paulus

Drug>Neutral Contrast



P value: uncorrected 0.001, FDR corrected 0.002

Multiple Tasks/Databases for Repeated Assessments

Contents lists available at ScienceDirect
NeuroImage
journal homepage: www.elsevier.com/locate/ynimg

It is never as good the second time around: Brain areas involved in salience processing habituate during repeated drug cue exposure in treatment engaged abstinent methamphetamine and opioid users

Hamed Ekhtiari, Rayus Kuplicki, Robin L. Aupperle, Martin P. Paulus

Discovery Sample



Replication Sample 1



Replication Sample 2

Replication Sample 2



Drug

Neutral





Developing a VICONS with Addiction Cue Reactivity



1. Networking: Involves communication and information exchange for mutual benefit
    - Sharing experiences through webinars
    - Sharing cue databases and tasks

(Afsarmanesh et al., 2005)

Developing a VICONS with Addiction Cue Reactivity

2. Coordination: Aligning / altering activities so that more efficient results are achieved

- Intervention Classification and Consensus



(Afsarmanesh et al., 2005)

Cue-based Intervention Classification and Consensus



ISAM-NIG Symposium 2021: Cue-based Cognitive Interventions

6 videos • 81 views • Last updated on Nov 24, 2021

International Society of Addiction Medicine (ISAM)

SUBSCRIBED

1

Hamed Ekhtiari — Cue-based Cognitive Interventions: the Current Status, Promises, and Challenges
International Society of Addiction Medicine (ISAM)

2 

Samantha Brooks—Neural Processes of Appetite Control: Data from Working Memory Training Intervention
International Society of Addiction Medicine (ISAM)

3

Parnian Rafei — Cue-induced Retrieval and Reconsolidation with Episodic Foresigh
International Society of Addiction Medicine (ISAM)

4

Victoria Manning— Cognitive Bias Modification for the Treatment of Alcohol Use D
International Society of Addiction Medicine (ISAM)

5

Antonio Verdejo-García— "The Future of Cue-based Interventions for Addiction Treatment"
International Society of Addiction Medicine (ISAM)

6

Serenella Tolomeo— Blunted Within-System and Increased Between-System Brain Abnormalities in AUD
International Society of Addiction Medicine (ISAM)

SCAN ME



E → A → S → I → Co → Re

Input **Output**

M

E: Environment; A: Attention;
S: Saliency Processing; M: Memory;
I: Interoception; Co: Control; Re: Response

Developing a VICONS with Addiction Cue Reactivity

2. Coordination: Aligning / altering activities so that more efficient results are achieved

- Intervention Nomenclature and Consensus
- fMRI Drug Cue Reactivity Methodological Checklist



(Afsarmanesh et al., 2005)

A Systematic Review on fMRI Drug Cue Reactivity Studies

Contributors: **Hamed Ekhtiari**, ACRI Secretariat

Date created: 2020-05-17 07:17 PM | Last Updated: 2021-05-02 12:21 PM

Create DOI

Category: Project

The Steering Committee (SC)

Hamed Ekhtiari

Anna Zilverstand

Andreas Heinz



Amy Janes



Hedy Kober

Lara Ray

Rajita Sinha

Joseph McClernon

Jane Joseph

Reagan Wetherill

Rita Goldstein



Elliot Stein

Martin Paulus

Anna Rose Childress

The Delphi Study; Making a Consensus





The Delphi Study; Making a Consensus





The Delphi Study; Making a Consensus





ENIGMA-ACRI Checklist: 7 categories, 38 items, 75 recommendations

Table B.1. Itemized list of main items for best practices and reporting

This checklist includes the items which are important to be reported and considered when conducting and reporting an fMRI drug cue reactivity (FDCR) study. This table grew out of a consensus among expert scientists in this field. Scientists are recommended to use this checklist to assess the quality of their study.

Categories	No.	Sub-Categories	Main Items to Report	Report
Participant Characteristics	1	Inclusion/Exclusion Criteria	Inclusion and exclusion criteria for all participant groups	
	2	Basic Demographics	Age **and** sex/gender for all participant groups	
	3	Advanced Demographics I	Education **or** a measurement of intelligence for all participant groups	
	4	Advanced Demographics II	Race **or** ethnicity for all participant groups	
	5	Psychiatric Profile	Any categorical or dimensional measurement of psychopathologies other than substance use disorder	
	6	Handedness	Handedness for all participant groups	
	7	Substance Use Profile-Main Drug	Route(s) of administration for the main substance (if it is obvious it doesn't need to be reported; i.e., there is only one route of administration for cigarette smokers or alcohol drinkers)	
	8	Substance Use Profile-Main Drug	Current **and** lifetime use pattern/severity for the main drug of use for all participant groups	
	9	Substance Use Profile-Other Drugs	Measures of current **or** lifetime use pattern/severity for drugs, other than the main drug of use, for all participant groups	
	10	Abstinence Status	Days/hours/minutes since last use (duration of abstinence) **and** how abstinence was verified for all participant groups	
	11	Addiction Treatment Status	Treatment status for all participant groups, (i.e., non-treatment seeking active users, treatment seeking active users, undergoing active treatment, treated and abstinent, relapsed after treatment, etc.)?	
General fMRI Information	12	fMRI pulse sequence and other acquisition details	Section for fMRI data acquisition details	
	13	fMRI preprocessing pipeline and other details	Section for fMRI preprocessing details	
	14	fMRI Data Processing	Section for MRI analyses and statistical modeling details	
	15	fMRI Data Reporting	Basic whole brain response to drug cues	
General Task Information	16	Task Design	Task structure (Event, Block or Mixed (events in blocks))	
	17	Number of Task Components	Number of runs (if more than one), blocks (for block-designed studies), and events (including drug cues, control cues, fixations, etc.)	
	18	Requested Engagement	Instructions to the study participants on how to engage with the cues	
	19	Temporal information of the event/block duration	Duration of each cue (for both event and blocked-design tasks) **and** the total block duration (for blocked-design tasks)	
	20	Temporal Information of the Task	Total task duration	
	21	Order of Blocks/Events	Order of block types (e.g., drug, control) (for blocked-designs) or event types (e.g., drug, control) (for event-related designs) (The order can be fully randomized (randomized and different between subjects), pseudorandomized (identical between subjects, but randomized once for the order of events/blocks), or not randomized (fixed order like neutral-drug-neutral-drug for all subjects)	
	22	Data and resource-sharing	Sharing the behavioral task code **or** source images	
Cue Information	23	Sensory Modality of Cues	Modality(ies) of utilized drug and neutral/control cues (The modalities can be word, picture, smell, taste, tactile, audio script, written script, imagination, silent video, audiovisual video, paraphernalia, substance itself, or mixed.)	
	24	Sources of Cues, Development	Source of drug and neutral/control cues	
	25	Sources of Cues, Validation	Extent of prior validation of drug and neutral/control cues used in the study (Drug and neutral/control cues in a study might be not validated, validated by assessing the craving induction of each cue individually using simple-item craving instruments like single-item VAS, or using standardized instruments of craving assessment and emotion or stress reactivity)	
	26	Drug and Neutral/Control Cue Content	Content of drug cues **and** its relationship to the targeted drug (These include stimulus related to the drug, stimulus related to instruments of drug use, stimulus related to various stages of drug use (i.e. "beginning" or "end" stimuli (lit cigarette vs. ashtray)), stimulus related to drug intake, stimulus related to typical drug consumption environments, stimulus related to preparation of drug, stimulus related to purchasing the drug, etc.)	
	27	Neutral/Control Matching to Drug-Cues for Physical Features	Factors for which drug and neutral/control cues have been matched (color, brightness, hue, content, complexity, scrambled drug cue, etc.)	
Craving Assessment Inside Scanner	28	Craving Assessment inside Scanner, Presence	Craving assessment inside the scanner	
	29	Craving Assessment inside Scanner, Time Points	Description of the Time points at which craving-related assessment is performed inside the scanner (e.g. before and/or after each cue/event/block/trial/scan/run/session) (Yes/No/Not Applicable [in case when there is no assessment inside the scanner])	
	30	Craving Assessment Inside Scanner, Instrument(s)	Description of the instrument(s) used to assess craving **and** craving-related constructs inside the scanner (Yes/No/Not Applicable [in case when there is no assessment inside the scanner])	
	31	Craving Assessment Inside Scanner, Technology	Description of the hardware used to obtain participant responses, with specifications of models and brands of devices, if necessary (e.g., response box, fiber-optic pad) (Yes/No/Not Applicable [in case when there is no assessment inside the scanner])	
Craving Assessment Outside Scanner	32	Craving Assessment Outside Scanner, Presence	Any craving-related assessment outside the scanner	
	33	Craving Assessment Outside Scanner, Time Points	Description of the time points at which craving-related assessment is performed outside the scanner (e.g., immediate before entering the scanner, immediately after exiting the scanner, etc.) (Yes/No/Not Applicable [in case when there is no assessment outside the scanner])	
	34	Craving Assessment Outside Scanner, Instrument(s)	Description of the instrument(s) used to assess craving **and** craving-related constructs outside the scanner (Yes/No/Not Applicable [in case when there is no assessment outside the scanner])	
Pre- and Post-scanning considerations	35	Pre-scanning Training and Familiarization	Procedure to train/familiarize participants with the task/scanner before the scanning	
	36	Pre-scanning Drug and Smoking Consumption	Whether participants were allowed to smoke or use other drugs prior to scanning	
	37	Other Tasks and Procedures in the Imaging Session	Presence **and** order of other tasks and procedures (e.g. resting fMRI or DTI before drug cue reactivity, familiarization, etc.) in the imaging session	
	38	Post-scanning Craving Management	Steps taken to reduce participant craving after performing the task	


a
Category 1: Participant Characteristics
1.1. Inclusion/Exclusion Criteria
1.2. Basic Demographics (Age and Sex/Gender)
1.3. Advanced Demographics I (Education and Intelligence)
1.4. Advanced Demographics II (Race/Ethnicity)
1.5. Psychiatric Profile (Disorders other than SUDs)
1.6. Handedness
1.7. Substance Use Profile-Main Drug, Route of Administration
1.8. Substance Use Profile-Main Drug, Pattern/ Severity
1.9. Substance Use Profile-Other Drugs
1.10. Abstinence Status
1.11. Addiction Treatment Status
Category 2: General fMRI Information
2.1. fMRI Pulse Sequence and other Acquisition Details
2.2. fMRI Preprocessing Pipeline and other Details
2.3. fMRI Data Processing
2.4. fMRI Data Reporting
Category 3: General Task Information
3.1. Task Design
3.2. Number of Task Components
3.3. Requested Engagement
3.4. Temporal Information of the Event/Block Duration
3.5. Temporal Information of the Task
3.6. Order of Blocks/Events
3.7. Data and Resource-Sharing
Category 4: Cue Information
4.1. Sensory Modality of Cues
4.2. Sources of Cues, Development
4.3. Sources of Cues, Validation
4.4. Drug Cues and Neutral/Control Stimuli Content
4.5. Drug Cues and Neutral Stimuli Matching for Physical Features
Category 5: Craving Assessment Inside Scanner
5.1. Craving Assessment Inside Scanner, Presence
5.2. Craving Assessment Inside Scanner, Time Points†
5.3. Craving Assessment Inside Scanner, Instrument(s)†
5.4. Craving Assessment Inside Scanner, Technology†
Category 6: Craving Assessment Outside Scanner
6.1. Craving Assessment Outside Scanner, Presence
6.2. Craving Assessment Outside Scanner, Time Points†
6.3. Craving Assessment Outside Scanner, Instrument(s)†
Category 7: Pre- and Post-Scanning Considerations
7.1. Pre-Scanning Training and Familiarization
7.2. Pre-Scanning Drug and Smoking Consumption
7.3. Other Tasks and Procedures in the Imaging Session
7.4. Post-Scanning Craving Management
94%
100%
72%
41%
92%
41%
75%
79%
87%
59%
76%
99%
99%
99%
65%
97%
96%
60%
94%
80%
77%
14%
97%
68%
27%
73%
50%
42%
96%
91%
40%
61%
88%
98%
25%
55%
91%
8%
0%
25%
50%
75%
100%
Articles that report a checklist item (%)
b
Frequency
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
1
2
3
8
32
52
9
1
0-10
11-20
21-30
31-40
41-50
51-60
61-70
71-80
81-90
91-100
Checklist items reported in articles (%)



nature protocols

CONSENSUS STATEMENT

https://doi.org/10.1038/s41596-021-00649-4

Check for updates

A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus

Hamed Ekhtiari[1,2✉], Mehran Zare-Bidoky[3,4,50], Arshiya Sangchooli[3,50], Amy C. Janes[5], Marc J. Kaufman[5], Jason A. Oliver[6,7,8], James J. Prisciandaro[9], Torsten Wüstenberg[10], Raymond F. Anton[9], Patrick Bach[11], Alex Baldacchino[12], Anne Beck[10,13], James M. Bjork[14], Judson Brewer[15], Anna Rose Childress[16], Eric D. Claus[17], Kelly E. Courtney[18], Mohsen Ebrahimi[3], Francesca M. Filbey[19], Dara G. Ghahremani[20], Peyman Ghobadi Azbari[3,21], Rita Z. Goldstein[22], Anna E. Goudriaan[23], Erica N. Grodin[20], J. Paul Hamilton[24,25], Colleen A. Hanlon[26], Peyman Hassani-Abharian[27], Andreas Heinz[10], Jane E. Joseph[28], Falk Kiefer[11], Arash Khojasteh Zonoozi[3,29], Hedy Kober[30], Rayus Kuplicki[1], Qiang Li[31], Edythe D. London[20], Joseph McClernon[6], Hamid R. Noori[32,33], Max M. Owens[34], Martin P. Paulus[1], Irene Perini[24,25], Marc Potenza[30,35,36,37], Stéphane Potvin[38], Lara Ray[20], Joseph P. Schacht[39], Dongju Seo[30], Rajita Sinha[30], Michael N. Smolka[40], Rainer Spanagel[41], Vaughn R. Steele[30], Elliot A. Stein[42], Sabine Steins-Loeber[43], Susan F. Tapert[18], Antonio Verdejo-Garcia[44], Sabine Vollstädt-Klein[11], Reagan R. Wetherill[16], Stephen J. Wilson[45], Katie Witkiewitz[46], Kai Yuan[47], Xiaochu Zhang[48,49] and Anna Zilverstand[2]

ENIGMA ACRI

Addiction Cue Reactivity Initiative

ENIGMA.ACRI@gmail.com

@ENIGMA_ACRI

Developing a VICONS with Addiction Cue Reactivity



3. Cooperation: Sharing resources for achieving compatible goals

- ENIGMA Mega Analysis

(Afsarmanesh et al., 2005)

github.com/mindandbrain/halfpipe

Welcome to ENIGMA `HALFpipe`

hosted singularity-hub | docker build passing | continuous integration passing | codecov 50%

`HALFpipe` is a user-friendly software that facilitates reproducible analysis of fMRI data, including preprocessing, single-subject, and group analysis. It provides state-of-the-art preprocessing using `fmriprep`, but removes the necessity to convert data to the `BIDS` format. Common resting-state and task-based fMRI features can then be calculated on the fly using `FSL` and `nipype` for statistics.

> **NOTE:** ENIGMA `HALFpipe` is pre-release software and not yet considered production-ready.
>
> If you would like to beta test and provide feedback, thank you! We recommend using Beta 6, as this has all new features and all the latest bug fixes. For a detailed list of changes, please see the changelog.
>
> If you encounter issues, please see the troubleshooting section of this document.
>
> To use a specific beta version, please use the following command to download HALFpipe.

Version	Installation
Beta 6 (December 8th 2020)	`singularity pull shub://mindandbrain/halfpipe:1.0.0b6` `docker pull mindandbrain/halfpipe:1.0.0b6`
Beta 5 (October 29th 2020)	`singularity pull shub://mindandbrain/halfpipe:1.0.0b5` `docker pull mindandbrain/halfpipe:1.0.0b5`
Beta 4 (October 1st 2020)	`singularity pull shub://mindandbrain/Halfpipe:1.0.0b4` `docker pull mindandbrain/halfpipe:1.0.0b4`

ENIGMA ACRI Databases

File Edit View Insert Format Data Tools Extensions Help Last edit was on July 19

90% $ % .0 .00 123 Calibri 11

A1:J1 fMRI Drug Cue-Reactivity Data Sharing

fMRI Drug Cue-Reactivity Data Sharing									
PI of the Database	Contact	PI's Institution, Country	No. Subjects	No. Sessions	Main Substance	Cue Type	Design	MRI Instrument	Format of the Ima
Hamed Ekhtiari/Martin Paulus	hekhtiari@laureateinstitute.org	Laureate Institute for Brain Research, USA	60	2	Opioid	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Hamed Ekhtiari/Martin Paulus	hekhtiari@laureateinstitute.org	Laureate Institute for Brain Research, USA	65	1	Methamphetam	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Jason Oliver	Jason-Oliver@ouhsc.edu	University of Oklahoma Health Sciences Center	40	1	Nicotine	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Patrick Bach	patrick.bach@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	98	2	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Patrick Bach	patrick.bach@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	35	2	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Sabine Vollstädt-Klein	s.vollstaedt-klein@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	14	2	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Sabine Vollstädt-Klein	s.vollstaedt-klein@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	22	2	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Sabine Vollstädt-Klein	s.vollstaedt-klein@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	71	1	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Sabine Vollstädt-Klein	s.vollstaedt-klein@zi-mannheim.de	Central Institute of Mental Health, Mannheim, Germany	92	2	Alcohol	Pictoral	Block	Siemens, MAGN	NIFTI
Markus Heilig	markus.heilig@liu.se	Center for Social and Affective Neuroscience, Linköping, Sweden	45	1	Alcohol	Pictorial	Block	Philips Ingenia 3	NIFTI
Xiaochu Zhang	zxcustc@ustc.edu.cn	University of Science and Technology of China, China	33	4	Nicotine	Pictorial	Event	Siemens Trio, 3 T	NIFTI
Xiaochu Zhang	zxcustc@ustc.edu.cn	University of Science and Technology of China, China	30	2	Alcohol	Pictorial	Event	GE MRI 750, 3 Te	NIFTI
Rita Goldstein	rita.goldstein@mssm.edu	Icahn School of Medicine at Mount Sinai	58	1	Cocaine	Words	event-related	Siemens, Skyra,	NIFTI
Rita Goldstein	rita.goldstein@mssm.edu	Icahn School of Medicine at Mount Sinai	58	1	Cocaine	Pictures	event-related	Siemens, Skyra,	NIFTI
Rita Goldstein	rita.goldstein@mssm.edu	Icahn School of Medicine at Mount Sinai	23	2 (MPH vs. placebo)	Cocaine	Words	Block	Varian, 4 Tesla	*hdr & *.img
Rita Goldstein	rita.goldstein@mssm.edu	Icahn School of Medicine at Mount Sinai	19	2 (baseline + 6 months f/u)	Cocaine	Words	Block	Varian, 4 Tesla	*hdr & *.img
Rita Goldstein	rita.goldstein@mssm.edu	Icahn School of Medicine at Mount Sinai	94	1	Cocaine	Words	Block	Varian, 4 Tesla	*hdr & *.img
Mohammad Ali Oghabian	oghabian@sina.tums.ac.ir	Tehran University of Medical Sciences, Iran	62	1	Methamphetam	Pictorial	Mixed (Event on	Siemens, MAGN	NIFTI
Marco Leyton	marco.leyton@mcgill.ca	McGill University	14	2 (d-amph vs. placebo)	Cocaine	Video	Block	Siemens, MAGN	NIFTI
Marco Leyton	marco.leyton@mcgill.ca	McGill University	15	1	Cocaine	Video	Block	Siemens, MAGN	NIFTI
Amy Janes	amy.janes@nih.gov	McLean Hospital/HarvardNIDA	70	1	Nicotine	Pictoral	Event-related	Siemens, Prisma	NIFTI
Kirsten Morley	kirsten.morley@sydney.edu.au	The University of Sydney, Australia	31	1	Alcohol	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Kirsten Morley	kirsten.morley@sydney.edu.au	The University of Sydney, Australia	53	1	Alcohol	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Kirsten Morley	kirsten.morley@sydney.edu.au	The University of Sydney, Australia	32	2	Alcohol	Pictorial	Block	GE MRI 750, 3 Te	NIFTI
Dara Ghahremani/Edythe London	darag@ucla.edu	UCLA	17	2	Methamphetam	Pictorial	event-related	Siemens, Prisma	NIFTI
Dara Ghahremani/Edythe London	darag@ucla.edu	UCLA	31	10 (abst+after smoking)	Nicotine	Video	event-related	Siemens, Trio, 3	NIFTI
Dara Ghahremani/Edythe London	darag@ucla.edu	UCLA	122	2 (abstinent + after smoking	Nicotine	Video	block	Siemens, Prisma	NIFTI
Dara Ghahremani/Edythe London	darag@ucla.edu	UCLA	31	3 (pre/post behav intervent	Cannabis	Pictorial	event-related	Siemens, Trio, 3	NIFTI
Eric Claus/Katie Witkiewitz	edc5208@psu.edu	The Mind Research Network/University of New Mexico, USA	150	4	Alcohol	Pictorial	Event	Siemens, MAGN	NIFTI/BIDS
Francesca Filbey	francesca.filbey@utdallas.edu	University of Texas at Dallas	207	1	Cannabis	Tactile	Block	Philips Achieva 3	NIFTI
Francesca Filbey	francesca.filbey@utdallas.edu	University of Texas at Dallas	99	1	Cannabis	Tactile	Block	GE MRI 750, 3 Te	NIFTI

Developing a VICONS with Addiction Cue Reactivity



3. Cooperation: Sharing resources for achieving compatible goals

- ENIGMA Mega Analysis
- Task Harmonization Task Force

(Afsarmanesh et al., 2005)

What do you think is the optimal range of length for the total duration of a standardized FDCR task (please give your answer in minutes)?

The mean length of the total task duration was 14.7 (±9.8) minutes. The median length was 12 min. The range was 5–52 minutes You may select a **range** of time on the sliders below:



use the ***first*** slider for the ***minimum*** and the **second** slider for the **maximum**

Minimum (minutes)

Maximum (minutes)

←

Survey Completion

0% 100%

→

Developing a VICONS with Addiction Cue Reactivity



3. Cooperation: Sharing resources for achieving compatible goals

- ENIGMA Mega Analysis
- Task Harmonization Task Force
- Biomarker Development Framework based on the FDA Qualification Pathway

(Afsarmanesh et al., 2005)

ENIGMA ACRI
Addiction Cue Reactivity Initiative

ISAM NIG
Neuroscience Interest Group

International Society of Addiction Medicine- Neuroscience Interest Group (ISAM-NIG)- 3rd Webinar

Biomarkers for Addiction Treatment Development:

fMRI Drug Cue Reactivity as an Example

In Collaboration with ENIGMA-ACRI Network

October 29th, 2020

ISAM
INTERNATIONAL SOCIETY OF ADDICTION MEDICINE
GLOBAL EXCELLENCE IN ADDICTION MEDICINE

ENIGMA Addiction

ACNP2021

Study Group:

Brains before brawn: Using brain-based, outcome-relevant, endophenotypes in Phase 2 medication development for psychiatric disorders – to improve our success in larger Phase 3 clinical trials.

Chair

Anna Rose Childress
University of Pennsylvania

Co-Chair/Moderator



Tanya Ramey
Medical officer, NIDA

Speaker

Mario Oquendo
University of Pennsylvania

Speaker

Diego Pizzagalli
Harvard Medical School

Speaker

Kathleen Brady
University of South California

Speaker

Joseph Schacht
University of Colorado

Speaker

Hamed Ekhtiari
Laureate Institute for Brain Research

Speaker

Gerard Moeller
Virginia Commonwealth University

Industry Speaker

Patricio O'Donnell
Takeda Pharma

Discussant

George Koob
Director, NIAAA

Discussant

Nora Volkow
Director, NIDA

SUN. 5 DEC. 3-5/30 PM (ET)


Sources of Evidence
1 - Systematic Reviews
2 - Expert Elicitation/Consensus
3 - Meta/Mega-Analyses
4 - New/Prospective Research
Discovery & Definition
Biomarker Specification[1,2]
Target Population
Demographic Criteria
Drug Use Profile
Clinical Characteristics
MRI and Task-related Criteria
Standard Operating Procedure
Abstinence status
Fasting
Familiarization procedures
Time of Day
Image Acquisition
MRI Device Properties
Imaging Protocol
Image Quality Control Criteria
Task Parameters
Analysis & Utilization
FCR Measure Specification
Image Preprocessing
fMRI Analysis Framework
Clinical Interpretation
Context of Use Specification[1,2]
Prognostic
Diagnostic
Severity
Natural Course
Disease Outcomes
Health
Disease
Monitoring
Susceptibility
Intervention
Physiological Effect
Treatment Outcomes
Predictive
Response (Pharmacodynamic)
Response (Surr. Endpoint)
Adverse Effects
Safety
Validation
Analytical Validation[1,3,4]
Accuracy/Precision
Subject, Operator, and Scanner Reliability
Natural FDCR Variation
Instrument/Random Error Modelling
Clinical Validation
Etiological Grounding of FDCR in Addiction[1]
Retrospective/Prospective Study Design[3,4]
Statistical Analysis Plan[2]
Cost-Benefit Analysis[1-3]
Drug Development Acceleration
Preclinical/Clinical Benefit
False Positive/Negative Cost
Scan Cost
Regulatory Qualification
Letter of Support
Drug Development Pathway
Letter of Intent (LOI)
Qualification Plan (QP)
Full Qualification Package (FQP)
FDA Qualification Framework
Institutional Review
Endorsement, Recommendation and Inclusion in Guidelines
Clinical Use Pathway
NIA/NIMH/NIAAA
SAMHSA
APA/ASAM
Qualification Announcement
Practice Guidelines
Application
FDCR as Drug Development Tool
FDCR in Direct Clinical Use
Use and Ongoing Evaluation/Optimization



4. Collaboration: Sharing information, resources and responsibilities to jointly plan, implement, and evaluate a program of activities to achieve a common goal

- Applying for FDA letter of interest

(Afsarmanesh et al., 2005)

Applying for FDA Letter of Interest







4. Collaboration: Sharing information, resources and responsibilities to jointly plan, implement, and evaluate a program of activities to achieve a common goal

- Applying for FDA letter of interest
- Developing a shared targeting map

(Afsarmanesh et al., 2005)

Defining Targets for Non-Invasive Brain Stimulation (NIBS) Interventions



Deep TMS



rTMS (Magnetic)



tES (tDCS/tACS)

INPAN
International Network of
tES/TMS Trials for Addiction Medicine

Optimized Non-Invasive Brain Stimulation for Addiction Treatment



WEDNESDAY	START AT	EASTERN TIME
27 July	10:00 AM	

SCAN ME

ISAM International Society of Addiction Medicine
ISAM Neuroscience Interest Group NIG
MEDICAL DISCOVERY TEAM ADDICTION
INTERNATIONAL tES-fMRI NETWORK

a. Lesion-based, Alcohol & Smoking



nature medicine

ARTICLES

https://doi.org/10.1038/s41591-022-01834-y

Check for updates

OPEN

Brain lesions disrupting addiction map to a common human brain circuit

Juho Joutsa[1,2,3,17]✉, Khaled Moussawi[4,5,17], Shan H. Siddiqi[3,6,17], Amir Abdolahi[7], William Drew[3,6], Alexander L. Cohen[3,6,8,9], Thomas J. Ross[4], Harshawardhan U. Deshpande[4], Henry Z. Wang[10], Joel Bruss[11], Elliot A. Stein[4], Nora D. Volkow[16], Jordan H. Grafman[12,13,14], Edwin van Wijngaarden[15], Aaron D. Boes[11] and Michael D. Fox[3,6]✉

a. Lesion-based, Alcohol & Smoking



nature medicine

ARTICLES

https://doi.org/10.1038/s41591-022-01834-y

Check for updates

OPEN

Brain lesions disrupting addiction map to a common human brain circuit

Juho Joutsa[1,2,3,17] ✉, Khaled Moussawi[4,5,17], Shan H. Siddiqi[3,6,17], Amir Abdolahi[7], William Drew[3,6], Alexander L. Cohen[3,6,8,9], Thomas J. Ross[4], Harshawardhan U. Deshpande[4], Henry Z. Wang[10], Joel Bruss[11], Elliot A. Stein[4], Nora D. Volkow[16], Jordan H. Grafman[12,13,14], Edwin van Wijngaarden[15], Aaron D. Boes[11] and Michael D. Fox[3,6] ✉

a. Lesion-based, Alcohol & Smoking



b. Cue-reactivity, Alcohol



c. Cue-reactivity, Smoking



d. Cue-reactivity, Methamphetamine



I. Importance of frontopolar: Evidence from fMRI maps

a. Lesion-based, Alcohol & Smoking

b. Cue-reactivity, Alcohol



c. Cue-reactivity, Smoking



d. Cue-reactivity, Methamphetamine



e. Cue-reactivity connections to frontopolar



I. Importance of frontopolar: Evidence from fMRI maps



II. Importance of frontopolar: Evidence from electrical field (EF) maps



a. Frontopolar activity in FDCR




a. Frontopolar activity in FDCR
b. Location and strength of 99th percentile of the EF
Frontopolar
Drug > Neutral
Averaged BOLD signal
15
10
5
0
Frontopolar area
Peak location
Peak location
99th percentile electric field in [V/m]
0.6
0.5
0.4
0.3
0.2
Montage 1 (F4-Fp1)
Montage 1 (F4-Fp1)
Montage 2 (F4-F3)
Montage 2 (F4-F3)



ISAM
INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

Developing More VICONS within ISAM GEN!

(Afsarmanesh et al., 2005)

frontiers in Psychiatry

REVIEW ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Psychiatry | doi: 10.3389/fpsyt.2019.00877

A Roadmap for Integrating Neuroscience into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine

Antonio Verdejo-García[1*], Valentina Lorenzetti[2], Victoria Manning[3, 4], Hugh Piercy[3, 4], Raimondo Bruno[5], Robert Hester[6], David Pennington[7], Serenella Tolomeo[8], Shalini Arunogiri[3, 4], Marsha E. Bates[9], Henrietta Bowden-Jones[10], Salvatore Campanella[11], Stacey Daughters[12], Christos Kouimtsidis[13], Dan I. Lubman[3], Dieter J. Meyerhoff[14], Annaketurah Ralph[15], Tara Rezapour[16], Hosna Tavakoli[16, 17], Mehran Zare-Bidoky[17, 18], Anna Zilverstand[19], J D. Steele[20], Scott J. Moeller[21], Alexander M. Baldacchino[8], Martin P. Paulus[22] and Hamed Ekhtiari[22]

Neuroscience and Biobehavioral Reviews 104 (2019) 118–140

Contents lists available at ScienceDirect

Neuroscience and Biobehavioral Reviews

journal homepage: www.elsevier.com/locate/neubiorev

Review article

Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead

Hamed Ekhtiari[a,*], Hosna Tavakoli[b,c], Giovanni Addolorato[d,e], Chris Baeken[f], Antonello Bonci[g,h,i], Salvatore Campanella[j], Luis Castelo-Branco[k], Gaëlle Challet-Bouju[l], Vincent P. Clark[m,n], Eric Claus[n], Pinhas N. Dannon[o], Alessandra Del Felice[p,q], Tess den Uyl[r], Marco Diana[s], Massimo di Giannantonio[t], John R. Fedota[u], Paul Fitzgerald[v], Luigi Gallimberti[w], Marie Grall-Bronnec[l], Sarah C. Herremans[f], Martin J. Herrmann[x], Asif Jamil[y], Eman Khedr[z], Christos Kouimtsidis[A], Karolina Kozak[B,C], Evgeny Krupitsky[D,E], Claus Lamm[F], William V. Lechner[G], Graziella Madeo[g], Nastaran Malmir[c], Giovanni Martinotti[t], William M. McDonald[H], Chiara Montemitro[g,t], Ester M. Nakamura-Palacios[I], Mohammad Nasehi[J], Xavier Noël[j], Masoud Nosratabadi[K], Martin Paulus[a], Mauro Pettorruso[t], Basant Pradhan[L], Samir K. Praharaj[M], Haley Rafferty[k], Gregory Sahlem[N], Betty jo Salmeron[g], Anne Sauvaget[O,P], Renée S. Schluter[a,b], Carmen Sergiou[Q], Alireza Shahbabaie[y], Christine Sheffer[R], Primavera A. Spagnolo[S], Vaughn R. Steele[u], Ti-fei Yuan[T], Josanne D.M. van Dongen[Q], Vincent Van Waes[U], Ganesan Venkatasubramanian[V], Antonio Verdejo-García[W], Ilse Verveer[Q], Justine W. Welsh[H], Michael J. Wesley[X], Katie Witkiewitz[n], Fateme Yavari[y], Mohammad-Reza Zarrindast[Y], Laurie Zawertailo[B,C], Xiaochu Zhang[Z], Yoon-Hee Cha[a], Tony P. George[B,C], Flavio Frohlich[aa], Anna E. Goudriaan[ab,ac], Shirley Fecteau[ad], Stacey B. Daughters[aa], Elliot A. Stein[u], Felipe Fregni[k], Michael A. Nitsche[y,ae], Abraham Zangen[af], Marom Bikson[ag], Colleen A. Hanlon[N]

medRxiv
THE PREPRINT SERVER FOR HEALTH SCIENCES
CSH Cold Spring Harbor Laboratory BMJ Yale

Neuroscience-Informed Classification of Prevention Interventions in Substance Use Disorders: An RDoC-based Approach

SCAN ME

Tara Rezapour, Parnian Rafei, Alex Baldacchino, Patricia J. Conrod, Geert Dom, Diana H. Fishbein, Ate
Vincent Hendriks, Nicola Newton, Nathaniel R. Riggs, Lindsay M. Squeglia, Maree Teesson, Jasmin Vas
Antonio Verdejo-Garcia, Hamed Ekhtiari

doi: https://doi.org/10.1101/2022.09.28.22280342









medRxiv
THE PREPRINT SERVER FOR HEALTH SCIENCES
CSH Cold Spring Harbor Laboratory BMJ Yale

Cognitive training and remediation interventions for substance use disorders: A Delphi consensus study

Antonio Verdejo-Garcia, Tara Rezapour, Emily Giddens, Arash Khojasteh Zonoozi, Parnian Rafe
Jamie Berry, Alfonso Caracuel, Marc L. Copersino, Matt Field, Eric L. Garland,
Valentina Lorenzetti, Leandro Malloy-Diniz, Victoria Manning, Ely M. Marceau,
David L. Pennington, Justin Strickland, Reinout Wiers, Rahia Fairhead, Alexandra Anderson,
Morris Bell, Wouter J. Boendermaker, Samantha Brooks, Raimondo Bruno, Salvatore Campa
Janna Cousijn, Miles Cox, Andrew C. Dean, Karen D Ersche, Ingmar Franken, Brett Froeliger,
Pedro Gamito, Thomas E. Gladwin, Priscila D. Goncalves, Katrijn Houben, Joanna Jacobus, Andrew Jones,
Anne M. Kaag, Johannes Lindenmeyer, Elly McGrath, Talia Nardo, Jorge Oliveira,
Charlotte R. Pennington, Kelsey Perrykkad, Hugh Piercy, Claudia I Rupp, Mieke H. J. Schulte,
Lindsay M. Squeglia, Petra Staiger, Dan J Stein, Jeff Stein, Maria Stein, William W. Stoops,
Mary Sweeney, Hoa Vo, Katie Witkiewitz, Steven P Woods, Richard Yi, Min Zhao, Hamed Ekhtiari

doi: https://doi.org/10.1101/2022.07.28.22278144

SCAN ME

Ten Take Home Notes

1. Start with defining the question through a series of webinars
2. Use systematic reviews to make a list of experts
3. Investigate systematic reviews to define the parameter space
4. Share your methodological experiences and protocols
5. Push methodological transparency as a goal
6. Explore potentials for methodological harmonization
7. Find platforms to share databases for mega analysis
8. Apply for joint funds and do something together
9. Support junior investigators and labs from developing countries/URM
10. Do not forget the main values of networking: diversity and sharing/caring

ISAM
INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

ISAM Global Expert Network GEN

Workshop

Expert Elicitation as a Research Tool

Towards Developing

World Addiction Medicine Report

November 11th, 2021

10:00 AM – 13:00 PM (ET, New York Time)

ORGANIZED BY ISAM GLOBAL EXPERT NETWORK (ISAM-GEN)

FREE REGISTRATION ON EVENTBRITE.COM

Willy Aspinall

Alex Baldacchino

Dimitris Christopoulos

Roger Cooke

Abigail Colson

Michael Coppedge

Cornelis A.J. DeJong

Lawrence D Phillips

Hamed Ekhtiari

Ali Farhoudian

Anca Hanea

Victoria Hemming

Arash Khojasteh Zonoozi

Samantha Low-Choy

David Nutt

Daniel Pemstein

Marc Potenza

Parnian Rafei

Arshiya Sangchooli

Marta Soares

SCAN ME

Inquiries:
isamgen@isamweb.org

ISAM Global Expert Network GEN

Scientific Methods in Global Surveys

2021 Talk Series

September 26 — DONE!

Expert Surveys as Measurment Tools

Mehran Zare-Bidoky
Arash Khojasteh Zonoozi

October 3 — DONE!

IDEA Protocol for Expert Elicitation

Jenna Butner
Ahmad Danesh

October 10 — DONE!

Expert Elicitation for Pandemic Modeling

Parnian Rafei
Ali Fathi Jouzdani

tober 17 — DONE!

PEST Tool for Expert Surveys

Aldo Alberto Conti
Preethy Kathiresan

tober 24

V-Dem Expert Elicitation Methods

Arshiya Sangchooli
Tomohiro Shirasaka

Register and join us from 8:30-9a EST on Zoom

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

ISAM NExT NEW PROFESSIONALS, EXPLORATION, TRAINING AND EDUCATION

World Addiction Medicine Report

terMyWall.com

WHAT
NOW?

Topic	Lead University	Lead Contact	Partner (Global/Regional Organizations)	Participants	Product
Societies/Organizations Basic Information Survey	Minnesota	Hamed Ekhtiari	ISAM RC	Societies/Organizations	Overview of societies/organizations
Opioid services, Phase 1	Minnesota	Hamed Ekhtiari	EUROPAD, NIDA	Societies/Organizations	Pilot Survey of ISAM-GEN
Education survey Training Needs	New Delhi	Roshan Bhad	ISAM NExT and Training Committee	Societies and Sample Clinicians	
Opioid services, Phase 2	Minnesota	Hamed Ekhtiari	EUROPAD, NIDA	Societies/Organizations	Pilot Survey of ISAM-GEN
MAT standards, 1-3	St Andrews	Alex Baldacchino	ISAM PPIG		
MAT standards, 4-6	St Andrews	Alex Baldacchino	ISAM PPIG		
MAT standards, 7-10	St Andrews	Alex Baldacchino	ISAM PPIG		
Psychiatric comorbidities, Phase 1	Barcelona	Marta Torrens	WPA, WADD		Delphi and Consensus
Psychiatric comorbidities, Phase 2	Barcelona	Marta Torrens	WPA, WADD		Delphi and Consensus
Non Pharmacological Addictions	Yale	Marc Potenza	Behavioral Addiction Interest Group		
Physical comorbidities, Phase 1	Monash		INHSU		Delphi
Physical comorbidities, Phase 2	Vancouver		INHSU		Delphi
Physical comorbidities, Phase 3			INHSU		Delphi
Alcohol services			NIAA		
Stimulants services	Monash	Shalini Arunogiri	ISAM South America Regional Rep (Dario)		
Cannabis services					
Quality Standards		Marica Ferri	UNODP, WHO, EMCDDA		
Burnout in Addiction Physicians	Yale	Marc Potenza	Robert Pietrzak (Yale)		
Post COVID Addiction Medicine		Multiple PIs			
Displaced Populations	St Andrews	Joe Tay			Delphi

Meet us at Networking Buffet Dinner tonight!

Master Courses on Addiction Treatment

Master Courses on Addiction Treatment



ISAM
INTERNATIONAL SOCIETY OF ADDICTION MEDICINE
GLOBAL EXCELLENCE IN ADDICTION MEDICINE

AMA
الجمعية المغربية لطب الإدمان
ⵜⴰⵎⵓⵔⵉⵜ ⵜⴰⵎⵖⵔⴰⴱⵉⵜ ⵏ ⵜⵓⵏⴳⴰⵎⵜ
ASSOCIATION MAROCAINE D'ADDICTOLOGIE
MOROCCAN ASSOCIATION OF ADDICTOLOGY

WELCOME TO THE XXVTH ANNUAL CONGRESS OF ISAM

XXV Years of Improving Care and Compassion in Addictions: 25 years of Global Focus and Perspectives

November 2th-4th, 2023 - Marrakech - Morocco

Q & A and Discussion

ISAM Global Expert Network GEN

ISAM INTERNATIONAL SOCIETY OF ADDICTION MEDICINE